ATE402715T1 - Hcv-impfstoff zusammensetzungen - Google Patents

Hcv-impfstoff zusammensetzungen

Info

Publication number
ATE402715T1
ATE402715T1 AT00975681T AT00975681T ATE402715T1 AT E402715 T1 ATE402715 T1 AT E402715T1 AT 00975681 T AT00975681 T AT 00975681T AT 00975681 T AT00975681 T AT 00975681T AT E402715 T1 ATE402715 T1 AT E402715T1
Authority
AT
Austria
Prior art keywords
hcv
charged
vaccine compositions
polyprotein
antigen
Prior art date
Application number
AT00975681T
Other languages
English (en)
Inventor
Debbie Drane
John Cox
Michael Houghton
Xavier Paliard
Original Assignee
Csl Ltd
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Ltd, Novartis Vaccines & Diagnostic filed Critical Csl Ltd
Application granted granted Critical
Publication of ATE402715T1 publication Critical patent/ATE402715T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00975681T 1999-11-19 2000-11-17 Hcv-impfstoff zusammensetzungen ATE402715T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16665299P 1999-11-19 1999-11-19
US22436200P 2000-08-11 2000-08-11

Publications (1)

Publication Number Publication Date
ATE402715T1 true ATE402715T1 (de) 2008-08-15

Family

ID=26862451

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00975681T ATE402715T1 (de) 1999-11-19 2000-11-17 Hcv-impfstoff zusammensetzungen

Country Status (12)

Country Link
US (2) US20040191270A1 (de)
EP (1) EP1239876B1 (de)
JP (1) JP2003514872A (de)
KR (1) KR100875483B1 (de)
AT (1) ATE402715T1 (de)
AU (1) AU772617B2 (de)
CA (1) CA2391843C (de)
DE (1) DE60039715D1 (de)
ES (1) ES2311478T3 (de)
HK (1) HK1047892B (de)
NZ (2) NZ518999A (de)
WO (1) WO2001037869A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE464907T1 (de) 1999-02-17 2010-05-15 Csl Ltd Immunogene komplexe und methoden in bezug auf diese
AU1236801A (en) * 1999-10-27 2001-05-08 Chiron Corporation Activation of hcv-specific t cells
AU2002322358B2 (en) * 2001-06-29 2009-06-18 Novartis Vaccines And Diagnostics, Inc. HCV E1E2 vaccine compositions
CA2471092A1 (en) * 2001-12-21 2003-07-10 Antigenics Inc. Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
ATE458496T1 (de) * 2002-01-14 2010-03-15 Novartis Vaccines & Diagnostic Hiv-vakzine und anwendungsverfahren
AU2003299994A1 (en) 2002-12-27 2004-07-29 Chiron Corporation Immunogenic compositions containing phospholpid
AU2004228476A1 (en) * 2003-04-11 2004-10-21 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Use of HCV proteins
KR100958505B1 (ko) * 2004-07-18 2010-05-17 씨에스엘 리미티드 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기위한 올리고뉴클레오티드 제제
CU23496A1 (es) * 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
US20070190072A1 (en) * 2004-09-30 2007-08-16 Csl Limited Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus adjuvant
JP2008516610A (ja) * 2004-10-18 2008-05-22 グローブイミューン，インコーポレイテッド 酵母を用いた慢性ｃ型肝炎感染の治療
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2200638B1 (de) * 2007-10-09 2016-03-16 The University of Melbourne Zusammensetzungen für die transfektion von zellen
NZ583377A (en) * 2007-10-12 2013-11-29 Csl Ltd Method of eliciting an immune response against pandemic influenza virus
WO2010033841A1 (en) 2008-09-19 2010-03-25 Globeimmune, Inc. Immunotherapy for chronic hepatitis c virus infection
WO2010115229A1 (en) * 2009-04-09 2010-10-14 The University Of Melbourne Immunogenic composition and uses thereof
WO2011136738A1 (en) 2010-04-30 2011-11-03 Temasek Life Sciences Laboratory Limited Universal vaccine against h5n1 lineages
CN103189072B (zh) 2010-09-22 2018-02-09 因纳瓦克私人有限公司 免疫刺激方法
CA2856565A1 (en) * 2010-11-26 2012-05-31 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd. Multimeric hepatitis virus (hcv) envelope 2 (e2) glycoprotein
CU24112B1 (es) * 2012-11-05 2015-08-27 Ct De Ingeniería Genética Y Biotecnología Antígenos vacunales quiméricos contra el virus de la hepatitis c
JP5931113B2 (ja) * 2014-04-08 2016-06-08 ザ ユニバーシティー オブ メルボルン 免疫原性組成物およびその使用
CN106749672B (zh) * 2016-11-18 2020-06-30 江西农业大学 一种丙型肝炎病毒融合抗原蛋白及其应用
ES3053993T3 (en) 2017-12-21 2026-01-28 Axelia Oncology Pty Ltd Optimised compounds
KR20220050873A (ko) 2019-06-26 2022-04-25 악셀리아 온콜로지 피티와이 리미티드 신규한 분자

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US5897873A (en) * 1984-04-12 1999-04-27 The Liposome Company, Inc. Affinity associated vaccine
US5583112A (en) * 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
WO1990001948A1 (en) * 1988-08-25 1990-03-08 The Liposome Company, Inc. Influenza vaccine and novel adjuvants
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US4981684A (en) * 1989-10-24 1991-01-01 Coopers Animal Health Limited Formation of adjuvant complexes
US5178860A (en) * 1989-09-01 1993-01-12 Coopers Animal Health Limited Adjuvant complexes and vaccine made therefrom
AU643141B2 (en) * 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5650398A (en) * 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
US5273965A (en) * 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins
ATE281526T1 (de) * 1993-05-05 2004-11-15 Common Services Agency Hepatitis-c virus typ 4,5 und 6
JPH08510240A (ja) * 1993-05-12 1996-10-29 カイロン コーポレイション Ｃ型肝炎ウイルスｅ２／ｎｓ１領域の保存モチーフ
US5451569A (en) * 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030050263A1 (en) * 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
SG71728A1 (en) * 1994-07-29 2000-04-18 Innogenetics Nv Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
AU686891B2 (en) * 1994-10-12 1998-02-12 Iscotec A.B. Saponin preparations and use thereof in iscoms
GB9620795D0 (en) * 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
GB9513261D0 (en) * 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
SE9600648D0 (sv) * 1996-02-21 1996-02-21 Bror Morein Receptorbimdande enhet
US6231859B1 (en) * 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
BR9809149A (pt) * 1997-05-20 2000-08-01 Galenica Pharmaceuticals Inc Análogos de triterpeno saponina dotados de adjuvante e atividade imonoestimulatória
WO1998052581A1 (en) * 1997-05-20 1998-11-26 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
CA2302554C (en) * 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
US20050031638A1 (en) * 1997-12-24 2005-02-10 Smithkline Beecham Biologicals S.A. Vaccine
IL139813A0 (en) * 1998-05-22 2002-02-10 Loeb Health Res Inst At The Ot Methods and products for inducing mucosal immunity
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
GB9817052D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
CA2340174C (en) * 1998-08-10 2011-01-04 Antigenics Llc Compositions of cpg and saponin adjuvants and methods thereof
FR2783170B1 (fr) * 1998-09-11 2004-07-16 Pasteur Merieux Serums Vacc Emulsion immunostimulante
ATE464907T1 (de) * 1999-02-17 2010-05-15 Csl Ltd Immunogene komplexe und methoden in bezug auf diese
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
AU1236801A (en) * 1999-10-27 2001-05-08 Chiron Corporation Activation of hcv-specific t cells
US6986892B1 (en) * 1999-11-24 2006-01-17 Chiron Corporation Immunogenic Hepatitis C virus non-structural polypeptides
FR2814958B1 (fr) * 2000-10-06 2003-03-07 Aventis Pasteur Composition vaccinale
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
US20030139364A1 (en) * 2001-10-12 2003-07-24 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
CA2471092A1 (en) * 2001-12-21 2003-07-10 Antigenics Inc. Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
AU2003230806B2 (en) * 2002-04-04 2009-05-07 Zoetis Belgium S.A. Immunostimulatory G,U-containing oligoribonucleotides
US7196892B2 (en) * 2002-04-10 2007-03-27 Caelin Gabriel Method and apparatus for isolating RFI, EMI, and noise transients in power supply circuits
CN1753687A (zh) * 2002-10-29 2006-03-29 科勒制药集团股份有限公司 Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
AU2004253479B9 (en) * 2003-06-17 2011-10-06 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes
EA200600069A1 (ru) * 2003-06-20 2006-08-25 Коли Фармасьютикал Гмбх Низкомолекулярные антагонисты toll-подобных рецепторов (tlr)
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
AU2004275876B2 (en) * 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
US20050215501A1 (en) * 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
KR100958505B1 (ko) * 2004-07-18 2010-05-17 씨에스엘 리미티드 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기위한 올리고뉴클레오티드 제제
EP1776105A2 (de) * 2004-07-18 2007-04-25 Coley Pharmaceutical Group, Ltd Verfahren und zusammensetzungen zur induzierung eigener immunantworten
US20070190072A1 (en) * 2004-09-30 2007-08-16 Csl Limited Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus adjuvant
WO2006110607A2 (en) * 2005-04-08 2006-10-19 Coley Pharmaceutical Group, Inc. Methods for treating infectious disease exacerbated asthma
DK2066341T3 (en) * 2006-09-01 2015-10-19 Csl Ltd PROCEDURE FOR INITIATING OR INDUCING AN IMMUNE RESPONSE

Also Published As

Publication number Publication date
DE60039715D1 (de) 2008-09-11
HK1047892A1 (en) 2003-03-14
AU772617B2 (en) 2004-05-06
EP1239876B1 (de) 2008-07-30
NZ520976A (en) 2005-01-28
US20040191270A1 (en) 2004-09-30
CA2391843C (en) 2011-10-18
NZ518999A (en) 2002-12-20
CA2391843A1 (en) 2001-05-31
HK1047892B (en) 2009-01-09
ES2311478T3 (es) 2009-02-16
KR20020073338A (ko) 2002-09-23
WO2001037869A1 (en) 2001-05-31
KR100875483B1 (ko) 2008-12-22
AU1373001A (en) 2001-06-04
EP1239876A1 (de) 2002-09-18
WO2001037869A9 (en) 2002-07-18
EP1239876A4 (de) 2003-05-02
US20100047271A1 (en) 2010-02-25
JP2003514872A (ja) 2003-04-22

Similar Documents

Publication Publication Date Title
ATE402715T1 (de) Hcv-impfstoff zusammensetzungen
EP1200109A4 (de) Verwendung von peptid-nukleinsäureverbindungen zur auslösung zellulärer immunantworten gegen hepatitis c
BG98523A (en) Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b
JP4734241B2 (ja) Ｈｃｖワクチン
ATE464907T1 (de) Immunogene komplexe und methoden in bezug auf diese
DK1362109T3 (da) Rekombinante oligomere protein-komplekser med foröget immunogent potentiale
AU4203201A (en) Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
MA27699A1 (fr) Vaccin contre vhc
WO2002013855A3 (en) Vaccines containing ribavirin and methods of use thereof
ATE320444T1 (de) Peptide, die die zytotoxische t-lymphozyte antwort gegen hepatitis-b-virus induzieren
ATE425187T1 (de) Materialien und methoden zur behandlung von hepatitis c
MXPA03009763A (es) Vacuna contra el virus de la enfermedad de la fiebre aftosa.
EP1572721A4 (de) Prävention und behandlung von hcv-infektionen unter anwendung von gegen konformationelle und lineare epitope gerichteten antikörpern
SE9903534D0 (sv) Vaccin
TW200509964A (en) VP1 of foot-and-mouth disease virus
NO971529L (no) Rekombinante proteiner av en Pakistani stamme av hepatitt E og deres anvendelse i diagnostiske metoder og vaksiner
DE69922212D1 (de) Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
WO2004058807A3 (en) Mhc class i restricted t-cell stimulating peptides from hepatitis b virus
ATE409705T1 (de) Pre-s-protein von hepatitis-b-virus (hbv) als adjuvans und komponente eines hbv-impfstoffs
RU2004104357A (ru) Вакцинный состав, потенцированный комбинацией днк и антигена
ATE413887T1 (de) Stress-protein-peptidkomplexe als impfstoffe gegen intrazelluläre pathogene
RU94038427A (ru) Пептиды, конъюгаты, фармацевтические композиции, способы лечения, способ идентификации
NO20042124L (no) Thymosinforsterkning ved genetisk immunisering
DK1237571T3 (da) Toscana-virus-nukleinprotein
EP1419784A3 (de) Proteasom-Impfstoffzusammensetzungen gegen Allergie, Krebs und Toxine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties